These genomic and transcriptomic alterations were clearly recapitulated by various GC cell lines [31], making them ideal preclinical models for exploring pharmacological effects of CDK4/6 inhibitors and drug screening for combination therapies in GC (Fig. 1D). This evidence concerns the gene CDK4 and gastric cancer.